Paolo Antonio S. Silva, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetic Retinopathy | 73 | 2023 | 1210 | 15.750 |
Why?
|
Macular Edema | 26 | 2023 | 359 | 7.920 |
Why?
|
Photography | 19 | 2023 | 520 | 4.580 |
Why?
|
Retinal Vessels | 16 | 2023 | 772 | 2.970 |
Why?
|
Fluorescein Angiography | 15 | 2023 | 940 | 2.580 |
Why?
|
Diabetes Mellitus | 14 | 2023 | 5751 | 2.460 |
Why?
|
Retina | 18 | 2023 | 2616 | 2.440 |
Why?
|
Diagnostic Techniques, Ophthalmological | 9 | 2019 | 245 | 2.040 |
Why?
|
Telemedicine | 16 | 2022 | 2872 | 2.010 |
Why?
|
Telepathology | 3 | 2016 | 76 | 1.580 |
Why?
|
Mydriatics | 5 | 2023 | 68 | 1.520 |
Why?
|
Laser Coagulation | 9 | 2017 | 326 | 1.310 |
Why?
|
Retinal Diseases | 6 | 2023 | 683 | 1.240 |
Why?
|
Visual Acuity | 15 | 2020 | 2530 | 1.170 |
Why?
|
Angiogenesis Inhibitors | 11 | 2018 | 2038 | 1.160 |
Why?
|
Ophthalmoscopy | 6 | 2018 | 176 | 1.150 |
Why?
|
Ophthalmology | 3 | 2022 | 508 | 1.130 |
Why?
|
Triamcinolone Acetonide | 5 | 2013 | 101 | 1.070 |
Why?
|
Retinal Neovascularization | 5 | 2015 | 244 | 1.070 |
Why?
|
Mydriasis | 2 | 2023 | 15 | 1.070 |
Why?
|
Vitrectomy | 9 | 2017 | 365 | 1.010 |
Why?
|
Tomography, Optical Coherence | 13 | 2023 | 2657 | 0.930 |
Why?
|
Diagnostic Imaging | 8 | 2021 | 3507 | 0.750 |
Why?
|
Retinal Hemorrhage | 3 | 2020 | 96 | 0.730 |
Why?
|
Vitreous Body | 5 | 2013 | 389 | 0.660 |
Why?
|
Pupil | 3 | 2016 | 149 | 0.650 |
Why?
|
Diabetes Mellitus, Type 1 | 11 | 2019 | 3336 | 0.640 |
Why?
|
Kallikrein-Kinin System | 2 | 2016 | 9 | 0.590 |
Why?
|
Vitreous Hemorrhage | 2 | 2015 | 48 | 0.570 |
Why?
|
Eye | 3 | 2023 | 729 | 0.560 |
Why?
|
Intravitreal Injections | 8 | 2018 | 344 | 0.550 |
Why?
|
Glucocorticoids | 4 | 2013 | 2107 | 0.530 |
Why?
|
Artificial Intelligence | 4 | 2023 | 2214 | 0.530 |
Why?
|
Cataract Extraction | 2 | 2017 | 481 | 0.470 |
Why?
|
Diagnosis, Computer-Assisted | 2 | 2016 | 719 | 0.470 |
Why?
|
Fundus Oculi | 7 | 2020 | 473 | 0.460 |
Why?
|
Retinal Vein Occlusion | 2 | 2014 | 137 | 0.460 |
Why?
|
Hemangioblastoma | 1 | 2013 | 70 | 0.440 |
Why?
|
Phacoemulsification | 1 | 2014 | 149 | 0.430 |
Why?
|
Lens Implantation, Intraocular | 1 | 2014 | 192 | 0.430 |
Why?
|
Severity of Illness Index | 14 | 2023 | 15540 | 0.430 |
Why?
|
Diabetes Complications | 3 | 2014 | 1359 | 0.420 |
Why?
|
Automation | 1 | 2015 | 584 | 0.420 |
Why?
|
Hyperlipidemias | 1 | 2017 | 789 | 0.420 |
Why?
|
von Hippel-Lindau Disease | 1 | 2013 | 152 | 0.420 |
Why?
|
Cataract | 2 | 2017 | 834 | 0.420 |
Why?
|
Physical Examination | 2 | 2015 | 1237 | 0.410 |
Why?
|
Retinal Neoplasms | 1 | 2013 | 144 | 0.400 |
Why?
|
Mass Screening | 3 | 2016 | 5255 | 0.390 |
Why?
|
Humans | 84 | 2023 | 744343 | 0.380 |
Why?
|
Sodium Chloride | 1 | 2013 | 625 | 0.370 |
Why?
|
Vascular Endothelial Growth Factor A | 10 | 2016 | 3508 | 0.370 |
Why?
|
Diabetes Mellitus, Type 2 | 12 | 2019 | 11725 | 0.360 |
Why?
|
Disease Progression | 9 | 2020 | 13284 | 0.310 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2015 | 8949 | 0.310 |
Why?
|
Polypharmacy | 1 | 2010 | 294 | 0.310 |
Why?
|
Vitreoretinal Surgery | 2 | 2017 | 27 | 0.290 |
Why?
|
Retrospective Studies | 20 | 2023 | 77449 | 0.280 |
Why?
|
Middle Aged | 36 | 2023 | 213383 | 0.280 |
Why?
|
Prospective Studies | 12 | 2023 | 53288 | 0.280 |
Why?
|
Intraocular Pressure | 3 | 2015 | 1270 | 0.270 |
Why?
|
Male | 39 | 2023 | 350118 | 0.260 |
Why?
|
Female | 39 | 2023 | 380194 | 0.240 |
Why?
|
Steroids | 1 | 2009 | 930 | 0.230 |
Why?
|
Ocular Hypertension | 1 | 2015 | 198 | 0.230 |
Why?
|
Sensitivity and Specificity | 6 | 2023 | 14722 | 0.230 |
Why?
|
Aged | 26 | 2023 | 163280 | 0.230 |
Why?
|
Cross-Sectional Studies | 10 | 2023 | 25043 | 0.220 |
Why?
|
Fluoresceins | 1 | 2023 | 235 | 0.220 |
Why?
|
Vision Disorders | 3 | 2014 | 1058 | 0.210 |
Why?
|
Color | 1 | 2023 | 307 | 0.200 |
Why?
|
United States Indian Health Service | 1 | 2021 | 32 | 0.200 |
Why?
|
Blood-Retinal Barrier | 1 | 2021 | 62 | 0.190 |
Why?
|
Adult | 25 | 2023 | 214055 | 0.190 |
Why?
|
Evidence-Based Medicine | 3 | 2017 | 3610 | 0.180 |
Why?
|
Eyelids | 1 | 2022 | 265 | 0.180 |
Why?
|
Antihypertensive Agents | 2 | 2015 | 2046 | 0.180 |
Why?
|
Uveitis | 1 | 2023 | 375 | 0.170 |
Why?
|
Choroid | 1 | 2020 | 322 | 0.160 |
Why?
|
Optics and Photonics | 2 | 2018 | 321 | 0.160 |
Why?
|
Glaucoma, Neovascular | 2 | 2015 | 36 | 0.160 |
Why?
|
Cohort Studies | 5 | 2023 | 40561 | 0.150 |
Why?
|
Aged, 80 and over | 10 | 2015 | 57776 | 0.140 |
Why?
|
Injections | 2 | 2010 | 840 | 0.140 |
Why?
|
Disease Management | 2 | 2017 | 2459 | 0.140 |
Why?
|
Plasma Kallikrein | 1 | 2016 | 20 | 0.140 |
Why?
|
Retreatment | 2 | 2015 | 610 | 0.140 |
Why?
|
Follow-Up Studies | 7 | 2020 | 39050 | 0.130 |
Why?
|
Vision, Low | 1 | 2017 | 168 | 0.130 |
Why?
|
Retinal Cone Photoreceptor Cells | 1 | 2016 | 177 | 0.130 |
Why?
|
Pseudophakia | 1 | 2014 | 62 | 0.120 |
Why?
|
Ciliary Body | 1 | 2015 | 173 | 0.120 |
Why?
|
Glaucoma Drainage Implants | 1 | 2015 | 116 | 0.120 |
Why?
|
Tropicamide | 1 | 2013 | 23 | 0.120 |
Why?
|
Computer Systems | 1 | 2015 | 483 | 0.110 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9274 | 0.110 |
Why?
|
Young Adult | 8 | 2018 | 56430 | 0.110 |
Why?
|
Phenylephrine | 1 | 2013 | 301 | 0.110 |
Why?
|
Hypoxia-Inducible Factor 1 | 1 | 2013 | 198 | 0.110 |
Why?
|
Signal Processing, Computer-Assisted | 3 | 2012 | 1534 | 0.110 |
Why?
|
Biological Availability | 2 | 2012 | 397 | 0.100 |
Why?
|
Capillary Permeability | 1 | 2016 | 798 | 0.100 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2013 | 290 | 0.100 |
Why?
|
Reproducibility of Results | 6 | 2020 | 19905 | 0.100 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 664 | 0.100 |
Why?
|
Health Status Disparities | 1 | 2023 | 1797 | 0.100 |
Why?
|
Retinal Detachment | 1 | 2015 | 411 | 0.090 |
Why?
|
Eye Proteins | 1 | 2013 | 646 | 0.090 |
Why?
|
Double-Blind Method | 3 | 2015 | 12026 | 0.090 |
Why?
|
ROC Curve | 1 | 2017 | 3527 | 0.080 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 2012 | 1572 | 0.080 |
Why?
|
Choroidal Neovascularization | 1 | 2012 | 343 | 0.080 |
Why?
|
Ubiquitin | 1 | 2013 | 852 | 0.080 |
Why?
|
Drug Combinations | 1 | 2013 | 1959 | 0.080 |
Why?
|
Glaucoma, Open-Angle | 1 | 2014 | 706 | 0.070 |
Why?
|
Combined Modality Therapy | 3 | 2013 | 8642 | 0.070 |
Why?
|
Specialization | 1 | 2012 | 777 | 0.070 |
Why?
|
Cost-Benefit Analysis | 2 | 2016 | 5391 | 0.070 |
Why?
|
Point-of-Care Systems | 1 | 2015 | 1177 | 0.070 |
Why?
|
Risk Factors | 5 | 2015 | 72290 | 0.070 |
Why?
|
Longitudinal Studies | 1 | 2022 | 13989 | 0.070 |
Why?
|
Glaucoma | 1 | 2016 | 1159 | 0.070 |
Why?
|
Case-Control Studies | 2 | 2022 | 21746 | 0.070 |
Why?
|
Recombinant Fusion Proteins | 1 | 2015 | 3772 | 0.070 |
Why?
|
Orbit | 1 | 2009 | 426 | 0.070 |
Why?
|
Adolescent | 4 | 2015 | 85781 | 0.070 |
Why?
|
Prevalence | 1 | 2021 | 15226 | 0.060 |
Why?
|
Tonometry, Ocular | 1 | 2015 | 237 | 0.060 |
Why?
|
Electronic Health Records | 1 | 2021 | 4468 | 0.060 |
Why?
|
Patient Satisfaction | 1 | 2016 | 3396 | 0.060 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2703 | 0.060 |
Why?
|
Aptamers, Nucleotide | 2 | 2016 | 166 | 0.060 |
Why?
|
Uvea | 1 | 2023 | 31 | 0.060 |
Why?
|
Age of Onset | 1 | 2010 | 3271 | 0.060 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 1518 | 0.060 |
Why?
|
Proteome | 1 | 2013 | 1799 | 0.060 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2016 | 3327 | 0.060 |
Why?
|
Recurrence | 1 | 2013 | 8340 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7279 | 0.050 |
Why?
|
Adrenal Cortex Hormones | 1 | 2009 | 1855 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2017 | 5137 | 0.040 |
Why?
|
Delivery of Health Care | 2 | 2023 | 5319 | 0.040 |
Why?
|
Treatment Outcome | 3 | 2013 | 63114 | 0.040 |
Why?
|
Hypoglycemic Agents | 1 | 2010 | 2872 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2013 | 15519 | 0.040 |
Why?
|
Canada | 1 | 2022 | 2065 | 0.040 |
Why?
|
Blood Glucose | 1 | 2010 | 6256 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2017 | 15295 | 0.030 |
Why?
|
Filtering Surgery | 1 | 2015 | 35 | 0.030 |
Why?
|
Time Factors | 1 | 2017 | 40075 | 0.030 |
Why?
|
Therapeutic Equivalency | 1 | 2015 | 141 | 0.030 |
Why?
|
Algorithms | 2 | 2016 | 13881 | 0.030 |
Why?
|
Carbonic Anhydrase I | 1 | 2013 | 4 | 0.030 |
Why?
|
Aldehyde Reductase | 1 | 2013 | 65 | 0.030 |
Why?
|
Models, Biological | 1 | 2010 | 9583 | 0.030 |
Why?
|
United States | 1 | 2021 | 69872 | 0.030 |
Why?
|
Ophthalmic Solutions | 1 | 2014 | 317 | 0.030 |
Why?
|
Ophthalmoscopes | 1 | 2012 | 23 | 0.030 |
Why?
|
Tenon Capsule | 1 | 2012 | 4 | 0.030 |
Why?
|
Injections, Intraocular | 1 | 2012 | 30 | 0.030 |
Why?
|
Depth Perception | 1 | 2012 | 94 | 0.030 |
Why?
|
Artifacts | 1 | 2020 | 1904 | 0.020 |
Why?
|
Lysophospholipids | 1 | 2013 | 331 | 0.020 |
Why?
|
Animals | 3 | 2021 | 168757 | 0.020 |
Why?
|
Pilot Projects | 1 | 2023 | 8324 | 0.020 |
Why?
|
Mutation | 1 | 2013 | 29786 | 0.020 |
Why?
|
Receptors, Immunologic | 1 | 2013 | 1423 | 0.020 |
Why?
|
Cattle | 1 | 2013 | 3922 | 0.020 |
Why?
|
Quality Assurance, Health Care | 1 | 2016 | 2212 | 0.020 |
Why?
|
Observer Variation | 1 | 2012 | 2593 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2013 | 2077 | 0.020 |
Why?
|
Macular Degeneration | 1 | 2012 | 980 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2012 | 2203 | 0.020 |
Why?
|
Collagen | 1 | 2013 | 2689 | 0.020 |
Why?
|
Hydrocortisone | 1 | 2012 | 1826 | 0.010 |
Why?
|
Neurons | 1 | 2021 | 9338 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2013 | 3479 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2012 | 3589 | 0.010 |
Why?
|
Computer Simulation | 1 | 2012 | 6196 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23403 | 0.010 |
Why?
|
Boston | 1 | 2010 | 9313 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2013 | 21827 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2013 | 17446 | 0.010 |
Why?
|
Mice | 1 | 2013 | 81183 | 0.000 |
Why?
|